Revenue growth has reversed sharply into a 36.0% decline as of 2024Q4, while operating margins have deteriorated to -68.6% from a peak of 61.5% in 2024Q2.
| Sales/Revenue | 16.11M | 9.76M | 8.19M | 6.71M | 23.54M | 4.43M |
| Revenue Growth % | - | 19.22% | 21.95% | -71.49% | 431.67% | - |
| Cost of Goods Sold | 6.11M | 1.25M | 2.3M | 3.35M | 10.98M | 1.89M |
| COGS % of Revenue | - | 12.76% | 28.1% | 49.93% | 46.64% | 42.6% |
| Gross Profit | 10M | 8.51M | 5.89M | 3.36M | 12.56M | 2.54M |
| Gross Margin % | 62.07% | 87.24% | 71.9% | 50.07% | 53.36% | 57.4% |
| Gross Profit Growth % | - | 44.65% | 75.11% | -73.25% | 394.25% | - |
| Operating Expenses | 5.72M | 2M | 3.89M | 1.4M | 2.37M | 86.09K |
| OpEx % of Revenue | - | 20.53% | 47.53% | 20.86% | 10.06% | 1.94% |
| Selling, General & Admin | 5.09M | 1.78M | 3.44M | 1.27M | 2.17M | 86.09K |
| SG&A % of Revenue | - | 18.2% | 41.98% | 18.85% | 9.21% | 1.94% |
| Research & Development | 637.19K | 227.19K | 454.23K | 134.7K | 200K | 0 |
| R&D % of Revenue | - | 2.33% | 5.55% | 2.01% | 0.85% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 4.27M | 6.51M | 2M | 1.96M | 10.2M | 2.46M |
| Operating Margin % | 26.53% | 66.7% | 24.38% | 29.22% | 43.3% | 55.46% |
| Operating Income Growth % | - | 226.22% | 1.76% | -80.77% | 315.15% | - |
| EBITDA | 4.7M | 6.51M | 2.57M | 1.97M | 10.2M | 2.54M |
| EBITDA Margin % | 29.15% | 66.7% | 31.36% | 29.41% | 43.33% | 57.26% |
| EBITDA Growth % | - | 153.61% | 30.03% | -80.65% | 302.31% | - |
| D&A (Non-Cash Add-back) | 13.03K | 0 | 0 | 13.04K | 6.25K | 0 |
| EBIT | 5M | 6.51M | 2.37M | 2.25M | 10.02M | 2.54M |
| Net Interest Income | 543.94K | 160.28K | 337.51K | 165.34K | 34.25K | 0 |
| Interest Income | 543.94K | 160.28K | 337.51K | 165.34K | 42.24K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 8K | 0 |
| Other Income/Expense | 725.2K | 717.46K | 377.48K | 292.78K | -184.41K | 79.94K |
| Pretax Income | 5M | 7.23M | 2.37M | 2.25M | 10.01M | 2.54M |
| Pretax Margin % | 31.03% | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 5M | 7.23M | 2.37M | 2.25M | 10.01M | 2.54M |
| Net Margin % | 31.03% | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Net Income Growth % | - | 204.56% | 5.29% | -77.49% | 294.79% | - |
| Net Income (Continuing) | 5M | 7.23M | 2.37M | 2.25M | 10.01M | 2.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.12 | 0.16 | 0.06 | 0.01 | 0.07 | 0.03 |
| EPS Growth % | - | 185.71% | 366.67% | -82.76% | 174.02% | - |
| EPS (Basic) | - | 0.16 | 0.06 | 0.02 | 0.07 | 0.03 |
| Diluted Shares Outstanding | 42.29M | 43.89M | 42.29M | 187.78M | 143.89M | 100M |
| Basic Shares Outstanding | 42.29M | 43.89M | 42.29M | 143.89M | 143.89M | 100M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Revenue volatility and scale
According to the most recent quarterly data, NNNN experienced a significant 36.0% revenue decline, signaling a sharp reversal from the 91.2% growth observed in 2024Q2 and highlighting the inherent instability of the company's current top-line performance in the post-pandemic diagnostic testing market environment.
The dramatic swing from high double-digit growth to a contraction suggests that the company's revenue base remains highly sensitive to seasonal demand or potential inventory destocking at the distributor level. Investors should monitor whether this deceleration represents a permanent shift in market demand or merely a temporary lull in the adoption of their multiplex diagnostic platforms.
As reported in financial statements, NNNN's gross margin fluctuated from 42.8% in 2023Q4 to a peak of 66.9% in 2024Q2, before settling at 84.6% in 2024Q4, suggesting that the company's cost structure is not yet optimized for consistent, scalable production of its diagnostic test kits.
While the 84.6% margin in the most recent quarter is impressive, the extreme variance across periods indicates that the company may be struggling with manufacturing efficiencies or fluctuating input costs. This lack of margin stability makes it difficult to forecast long-term profitability and suggests that the company's pricing power may be inconsistent across different product batches.
Based on NNNN's reported figures, the company's operating income swung from a positive $3.9M in 2024Q2 to a loss of $1.7M in 2024Q4, demonstrating that the firm currently lacks the operating leverage required to maintain profitability during periods of declining top-line revenue.
The sharp increase in SG&A expenses to $3.5M in 2024Q4, despite falling revenue, indicates that the company's cost base is relatively fixed and does not scale down effectively. This suggests that management may be over-investing in overhead relative to the current revenue scale, which warrants further investigation into their long-term expense discipline.
Financial data indicates that NNNN's net income has been highly erratic, shifting from a $3.9M profit in 2024Q2 to a $1.3M loss in 2024Q4, which raises concerns regarding the sustainability of the company's earnings model and the reliability of its short-term financial reporting.
The rapid transition from significant profitability to net losses suggests that the company's bottom line is highly susceptible to non-operating items or sudden shifts in operational efficiency. Investors should be cautious, as the lack of consistent earnings history makes it difficult to determine if the company can achieve a sustainable, profitable growth trajectory.
Quick answers to the most common questions about buying NNNN stock.
For fiscal year 2025, Anbio Biotechnology Class A Ordinary Shares (NNNN) reported total revenue of $9.8M. This represents a 120.4% increase compared to $4.4M in 2021.
Anbio Biotechnology Class A Ordinary Shares (NNNN) is profitable, generating $7.2M in net income for the fiscal year ending 2025 with a net profit margin of 74.1%.
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported an operating income of $6.5M, resulting in an operating profit margin of 66.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Anbio Biotechnology Class A Ordinary Shares (NNNN) generated $8.5M in gross profit for the year, representing a gross profit margin of 87.2%. This demonstrates the company's core pricing power and production efficiency.